Total Payments
$15,469
2024 Payments
$1,897
Companies
49
Transactions
688
Medicare Patients
13,717
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$15,430 (99.7%)
Education$39.10 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,430 | 682 | 99.7% |
| Education | $39.10 | 6 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,760 | 92 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,443 | 55 | $0 (2024) |
| Amgen Inc. | $1,436 | 82 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,422 | 78 | $0 (2024) |
| Abbott Laboratories | $1,277 | 13 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $884.39 | 36 | $0 (2024) |
| PFIZER INC. | $874.31 | 30 | $0 (2024) |
| Amarin Pharma Inc. | $709.00 | 37 | $0 (2022) |
| Boston Scientific Corporation | $595.72 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $535.39 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,897 | 76 | Abbott Laboratories ($275.26) |
| 2023 | $1,302 | 64 | E.R. Squibb & Sons, L.L.C. ($180.01) |
| 2022 | $1,656 | 86 | Novartis Pharmaceuticals Corporation ($285.64) |
| 2021 | $1,633 | 96 | Boehringer Ingelheim Pharmaceuticals, Inc. ($230.70) |
| 2020 | $978.45 | 53 | Amarin Pharma Inc. ($194.83) |
| 2019 | $1,936 | 92 | Novartis Pharmaceuticals Corporation ($287.88) |
| 2018 | $3,106 | 107 | Boehringer Ingelheim Pharmaceuticals, Inc. ($399.52) |
| 2017 | $2,960 | 114 | Abbott Laboratories ($389.25) |
All Payment Transactions
688 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $27.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/16/2024 | Vital Connect, Inc | VITALPATCH RTM (Device) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: CARDIOLOGY | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $28.40 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $9.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Genetic Disease | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $4.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/18/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: Cardiovascular Diseases | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $6.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.06 | General |
| Category: Cardiovascular | ||||||
| 10/17/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/15/2024 | Abbott Laboratories | AMPLATZER AMULET (Device) | Food and Beverage | In-kind items and services | $36.00 | General |
| Category: Structural Heart | ||||||
| 10/03/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $14.61 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Not Applicable | ||||||
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.03 | General |
| Category: Cardiovascular | ||||||
| 09/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: Cardio-renal | ||||||
| 09/12/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Genetic Disease | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 3,553 | 5,330 | $1.0M | $420,894 |
| 2022 | 30 | 3,801 | 5,833 | $979,124 | $421,127 |
| 2021 | 29 | 3,358 | 5,246 | $980,733 | $432,477 |
| 2020 | 27 | 3,005 | 4,449 | $770,418 | $323,916 |
Total Patients
13,717
Total Services
20,858
Medicare Billing
$1.6M
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 485 | 854 | $149,450 | $78,950 | 52.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 243 | 440 | $99,000 | $57,249 | 57.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 154 | 155 | $124,000 | $52,852 | 42.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 269 | 273 | $163,800 | $40,267 | 24.6% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 154 | 310 | $46,500 | $27,017 | 58.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 166 | 177 | $57,525 | $24,521 | 42.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 121 | 123 | $36,900 | $18,542 | 50.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 101 | 183 | $36,600 | $17,725 | 48.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 142 | 268 | $29,480 | $17,353 | 58.9% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 87 | 348 | $22,032 | $14,830 | 67.3% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 17 | 17 | $17,850 | $11,349 | 63.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 175 | 180 | $48,240 | $8,941 | 18.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 147 | 147 | $44,100 | $7,793 | 17.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 61 | 61 | $16,775 | $7,273 | 43.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 467 | 535 | $26,215 | $5,758 | 22.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 21 | 21 | $7,875 | $4,692 | 59.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 484 | 621 | $24,840 | $4,092 | 16.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 14 | 22 | $7,700 | $3,887 | 50.5% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 19 | 130 | $7,150 | $3,735 | 52.2% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 34 | 107 | $5,885 | $2,318 | 39.4% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 39 | 125 | $6,250 | $2,087 | 33.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 29 | 32 | $3,840 | $1,972 | 51.3% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 11 | 79 | $3,950 | $1,601 | 40.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 16 | 17 | $2,550 | $1,542 | 60.5% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 14 | 15 | $3,750 | $1,493 | 39.8% |
About Dr. Htwe Sein, M.D
Dr. Htwe Sein, M.D is a Cardiovascular Disease healthcare provider based in Palm Beach Gardens, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376584185.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Htwe Sein, M.D has received a total of $15,469 in payments from pharmaceutical and medical device companies, with $1,897 received in 2024. These payments were reported across 688 transactions from 49 companies. The most common payment nature is "Food and Beverage" ($15,430).
As a Medicare-enrolled provider, Sein has provided services to 13,717 Medicare beneficiaries, totaling 20,858 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Palm Beach Gardens, FL
- Active Since 06/10/2006
- Last Updated 05/29/2008
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1376584185
Products in Payments
- ENTRESTO (Drug) $1,483
- XARELTO (Drug) $1,422
- JARDIANCE (Drug) $1,020
- ELIQUIS (Drug) $972.33
- Repatha (Biological) $822.36
- Vascepa (Drug) $709.00
- Corlanor (Drug) $613.31
- Mitra Clip system (Device) $563.95
- PRADAXA (Drug) $422.79
- MULTAQ (Drug) $359.33
- WATCHMAN (Device) $351.67
- NORTHERA (Drug) $346.26
- CAMZYOS (Drug) $321.28
- VERQUVO (Drug) $316.78
- VYNDAQEL (Drug) $278.47
- LEQVIO (Drug) $276.79
- Livalo (Drug) $265.08
- FARXIGA (Drug) $252.41
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $223.35
- BRILINTA (Drug) $220.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Palm Beach Gardens
Dr. Morteza Tavakol, M.d, M.D
Cardiovascular Disease — Payments: $199,306
Cardiovascular Disease $199,306
Steven Kessel, M.d, M.D
Cardiovascular Disease — Payments: $14,724
Cardiovascular Disease $14,724
Cyrus Kavasmaneck, Md, MD
Cardiovascular Disease — Payments: $9,976
Cardiovascular Disease $9,976
Tobia Palma, M.d, M.D
Cardiovascular Disease — Payments: $4,590
Cardiovascular Disease $4,590
Dr. Richard Price, Md, MD
Cardiovascular Disease — Payments: $1,698
Cardiovascular Disease $1,698